This account is pending registration confirmation. Please click on the link within the confirmation email previously sent you to complete registration. Need a new registration confirmation email? Click here
SALT LAKE CITY, Nov. 18, 2010 (GLOBE NEWSWIRE) -- Myrexis, Inc. (Nasdaq:MYRX), a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer, today announced that Adrian Hobden, Ph.D., President and Chief Executive Officer, is scheduled to present an overview of the Company at the Piper Jaffray Health Care Conference, taking place November 30 and December 1, 2010.
Dr. Hobden and Robert Lollini, Chief Financial Officer and Treasurer, will be available to participate in one-on-one meetings with investors attending the conference.
Event: 22nd Annual Piper Jaffray Health Care Conference
Date: Wednesday, December 1, 2010
Time: 2:30pm ET
Place: The New York Palace Hotel, New York City
The presentation will be audio webcast live and can be accessed by visiting the investor relations section of Myrexis' website at
www.myrexis.com . The webcast will be archived for 90 days.
About Myrexis, Inc.
Myrexis, Inc. is a biotechnology company focused on discovering, developing, and commercializing novel treatments for cancer. The Company has leveraged a unique understanding of the genetic causes of human disease to generate a robust pipeline of clinical and pre-clinical product candidates. These include compounds with distinct mechanisms of action and novel chemical structures that have first-in-class and/or best-in-class therapeutic potential. Myrexis is led by an experienced management team with expertise in human genetics, protein-protein interaction technology, chemical proteomics, drug discovery and clinical and commercial development.
The Company's oncology pipeline is led by
Azixa (verubulin, MPC-6827), a novel small molecule microtubule destabilizing agent in Phase 2 clinical development for the treatment of brain cancers. Additional novel, potent, small molecule oncology compounds include
MPC-3100, a fully-synthetic inhibitor of Hsp90 in Phase 1; and
MPC-9528, a Cancer Metabolism Inhibitor (CMI) in IND-enabling studies. Myrexis is also evaluating
MPI-0485520, an orally bioavailable, potent and selective small molecule inhibitor of type I interferon production that is being developed for cancer and chronic inflammation.
For more information, please visit
Myrexis and the Myrexis logo are trademarks or registered trademarks of Myrexis, Inc. in the United States and foreign countries